Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients

Nephrology Dialysis Transplantation

Volumn 18, Issue SUPPL. 3, 2003, Pages

  Shiizaki, Kazuhiro ^a   Negi, Shigeo ^a   Mizobuchi, Masahide ^a   Hatamura, Ikuji ^a   Narukawa, Nobuhiko ^a   Sakaguchi, Toshifumi ^a   Kitabata, Yukiko ^a   Sumikado, Shinji ^a   Akizawa, Tadao ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Calcitriol; End stage renal disease (ESRD); Interventional ultrasonography; Renal osteodystrophy; Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; AGED; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; ORGAN SIZE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PERCUTANEOUS DRUG ADMINISTRATION; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; UREMIA;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; CALCITRIOL; CALCIUM CHANNEL AGONISTS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PARATHYROID GLANDS; PARATHYROID HORMONE; TIME FACTORS; UREMIA;

EID: 0038015179     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Slatopolsky EA, Burke SK, Dillon MA et al. RenaGel®, a nonabsorbed calcium- and aluminium-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55: 299-307
2. 3 on secondary hyperparathyroidism in hemodialysis patients: one-year administration study. Nephrol Dial Transplant 2002; 17
3. Koshikawa S, Akizawa T, Kurokawa K et al. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. Nephron 2002; 90: 413-423
4. Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-1024
5. Kitaoka M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994; 46: 1110-1117
6. WAF1 and TGF-α mediate parathyroid growth arrested by vitamin D and high calcium. Kidney Int 2001; 60: 2109-2117
7. Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate and vitamin D. J Clin Invest 1995; 96: 1786-1793
8. Fukagawa M, Okazaki R, Takano K et al. Regression of parathyroid hypertrophy by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 1990; 323: 421-422
9. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973; 15: 643-646
10. Rao DS, Shin MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328: 171-175
11. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
12. Kitaoka M, Fukagawa M, Fukuda N et al. Direct calcitriol injections into enlarged parathyroid glands in chronic dialysis patients with severe parathyroid hyperfunction. Nephrology 1995; 1: 563-567
13. Shiizaki K, Hatamura I, Negi S et al. Clinical effects and changes of parathyroid cells induced by percutaneous maxacalcitol injection therapy (PMIT) in patients with secondary hyperparathyroidism. (2HPT). J Am Soc Nephrol 2002; 13: 194A
14. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1443
15. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
16. Levine S, Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996; 7: 488-496
17. Patel R, Ke Q, Hsu H. Regulation of calcitriol receptor and mRNA in normal and renal failure rats. Kidney Int 1994; 45: 1020-1027